Citadel Advisors
GH icon

Citadel Advisors’s Guardant Health GH Stock Holding History

Citadel Advisors’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.15M Sell
23,300
-40,500
-63% -$4.07M ﹤0.01% 5927
2025
Q4 		$6.52M Sell
63,800
-31,000
-33% -$2.77M ﹤0.01% 3875
2025
Q3 		$5.92M Sell
94,800
-26,200
-22% -$1.43M ﹤0.01% 4045
2025
Q2 		$6.3M Buy
121,000
+60,900
+101% +$2.72M ﹤0.01% 3729
2025
Q1 		$2.56M Sell
60,100
-25,200
-30% -$1.09M ﹤0.01% 5057
2024
Q4 		$2.61M Sell
85,300
-48,400
-36% -$1.36M ﹤0.01% 5094
2024
Q3 		$3.07M Sell
133,700
-17,500
-12% -$495K ﹤0.01% 4739
2024
Q2 		$4.37M Buy
151,200
+60,400
+67% +$1.41M ﹤0.01% 3962
2024
Q1 		$1.87M Buy
90,800
+50,000
+123% +$1.07M ﹤0.01% 5657
2023
Q4 		$1.1M Sell
40,800
-5,600
-12% -$147K ﹤0.01% 6476
2023
Q3 		$1.38M Sell
46,400
-11,100
-19% -$390K ﹤0.01% 5939
2023
Q2 		$2.06M Sell
57,500
-36,000
-39% -$1.03M ﹤0.01% 5101
2023
Q1 		$2.19M Sell
93,500
-89,500
-49% -$2.56M ﹤0.01% 5184
2022
Q4 		$4.98M Sell
183,000
-38,700
-17% -$1.77M ﹤0.01% 3870
2022
Q3 		$11.9M Buy
221,700
+162,700
+276% +$8.35M ﹤0.01% 2511
2022
Q2 		$2.38M Sell
59,000
-15,000
-20% -$743K ﹤0.01% 5207
2022
Q1 		$4.9M Buy
74,000
+14,700
+25% +$1.01M ﹤0.01% 4213
2021
Q4 		$5.93M Buy
59,300
+36,300
+158% +$3.75M ﹤0.01% 4004
2021
Q3 		$2.88M Sell
23,000
-35,900
-61% -$4.27M ﹤0.01% 5470
2021
Q2 		$7.32M Sell
58,900
-21,200
-26% -$2.85M ﹤0.01% 3660
2021
Q1 		$12.2M Buy
80,100
+21,000
+36% +$3.17M ﹤0.01% 2684
2020
Q4 		$7.62M Sell
59,100
-36,600
-38% -$4.21M ﹤0.01% 3017
2020
Q3 		$10.7M Buy
95,700
+34,900
+57% +$3.19M ﹤0.01% 2211
2020
Q2 		$4.93M Buy
60,800
+8,600
+16% +$693K ﹤0.01% 3097
2020
Q1 		$3.63M Buy
52,200
+7,300
+16% +$560K ﹤0.01% 3171
2019
Q4 		$3.51M Sell
44,900
-15,100
-25% -$1.09M ﹤0.01% 3568
2019
Q3 		$3.83M Buy
60,000
+31,400
+110% +$2.77M ﹤0.01% 3490
2019
Q2 		$2.47M Sell
28,600
-3,300
-10% -$252K ﹤0.01% 4160
2019
Q1 		$2.45M Buy
+31,900
New +$1.77M ﹤0.01% 4119

Other funds holding GH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's GH Position: Q1 2026 in Review

Citadel Advisors increased its Guardant Health (GH) stake by 37% in Q1 2026, buying an estimated $21.2M and bringing the position to 775,941 shares worth $71.7M. The position accounts for 0.01% of the portfolio, ranked #1059.

Citadel Advisors first reported a position in GH in Q1 2019 and has held it in 28 quarters since. The position peaked at $153M in Q1 2025. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.

  • Citadel Advisors held 775,941 shares of Guardant Health worth $71.7M as of Q1 2026.
  • Citadel Advisors bought 211,599 Guardant Health shares in Q1 2026, an estimated $21.2M.
  • Guardant Health made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1059 holding.
  • Citadel Advisors first reported a position in Guardant Health in Q1 2019 and has held it in 28 quarters since.
  • Citadel Advisors's Guardant Health position peaked at $153M in Q1 2025.
  • 481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.